Back
Vanguard FTSE Developed Markets ETF Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Sell
49
VEA
Vanguard FTSE Developed Markets ETF
Last Price:
50.29
Seasonality Move:
1.57%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
270.06
Seasonality Move:
13.19%
Sell
49
Vanguard FTSE Developed Markets ETF (VEA)
is a Sell
Is Vanguard FTSE Developed Markets ETF a Buy, Sell or Hold?
- The current Vanguard FTSE Developed Markets ETF [VEA] share price is $50.21. The Score for VEA is 49, which is 2% below its historic median score of 50, and infers higher risk than normal.
- VEA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $273.91. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
VEA Stock Price Chart
What is Vanguard FTSE Developed Markets ETF's stock price today?
-
The Vanguard FTSE Developed Markets ETF share price today is $50.21
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and VEA is experiencing selling pressure, which indicates risk of future bearish movement.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $273.91
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and ALNY is experiencing buying pressure, which is a positive indicator for future bullish movement.
VEA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.4 | Sell |
| Relative Strength Index (14 RSI): | 35.55 | Sell |
| Chaikin Money Flow: | -5706696 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (50.68 - 52.16) | Sell |
| Bollinger Bands (100): | (49.65 - 52.01) | Sell |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.53 | Buy |
| Relative Strength Index (14 RSI): | 44.14 | Sell |
| Chaikin Money Flow: | 854887 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (270.99 - 291.37) | Sell |
| Bollinger Bands (100): | (223 - 289.2) | Buy |
VEA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 50.5 | Sell |
| 20-day SMA: | 51.19 | Sell |
| 50-day SMA: | 51.64 | Sell |
| 200-day SMA: | 50.01 | Buy |
| 8-day EMA: | 50.56 | Sell |
| 20-day EMA: | 51.03 | Sell |
| 50-day EMA: | 51.23 | Sell |
| 200-day EMA: | 49.87 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 283.39 | Sell |
| 20-day SMA: | 283.12 | Sell |
| 50-day SMA: | 274.41 | Sell |
| 200-day SMA: | 205.7 | Buy |
| 8-day EMA: | 280.46 | Sell |
| 20-day EMA: | 281.6 | Sell |
| 50-day EMA: | 272.95 | Buy |
| 200-day EMA: | 226.73 | Buy |
Vanguard FTSE Developed Markets ETF Earnings Growth & VEA Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.86 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.48 per share, and an increase next year of $0.66 per share.
Vanguard FTSE Developed Markets ETF Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Oct 21 | Oct 22 | Oct 23 | Oct 24 | Oct 25 | Oct 28 | Oct 29 | Oct 30 | Oct 31 | Nov 1 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 21 | 22 | 23 | 24 | 25 | 28 | 29 | 30 | 31 | 01 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||